drugset / Trial / NCT04809233

Expanded Access to Tipifarnib

NCT04809233

Expanded access Available Kura Oncology, Inc.

Summary

Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL). To request access, use Responsible Party contact information provided in this record. Expanded access for tipifarnib is only available in the United States.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background tipifarnib Small molecule